Regeneron Pharmaceuticals, Inc. - REGN
About Gravity Analytica
Recent News
- 06.13.2025 - 2025 Annual Meeting of Shareholders
- 06.09.2025 - 46th Annual Goldman Sachs Global Healthcare Conference
- 06.07.2025 - Dupixent® (dupilumab) Data at Revolutionizing Atopic Dermatitis (RAD) Conference Reinforce Use in Atopic Dermatitis Patients with Skin of Color
- 06.02.2025 - Regeneron Expands Clinical-Stage Obesity Portfolio with Strategic In-Licensing of Novel Dual GLP-1/GIP Receptor Agonist
- 06.02.2025 - Interim Results from Ongoing Phase 2 COURAGE Trial Confirm Potential to Improve the Quality of Semaglutide (GLP-1 receptor agonist)-induced Weight Loss by Preserving Lean Mass
- 05.31.2025 - Libtayo® (cemiplimab) Phase 3 Data in the Adjuvant Treatment of Post-Surgical High-Risk Cutaneous Squamous Cell Carcinoma (CSCC) Have Potential to Be Practice-Changing
- 05.30.2025 - Itepekimab Met Primary Endpoint in One of Two Chronic Obstructive Pulmonary Disease (COPD) Phase 3 Trials
- 05.28.2025 - Bernstein 41st Annual Strategic Decisions Conference
- 05.28.2025 - Bernstein 41st Annual Strategic Decisions Conference
- 05.22.2025 - Linvoseltamab in Combination with Carfilzomib or Bortezomib Shows Promising Initial Results in Earlier Lines of Treatment for Relapsed/Refractory Multiple Myeloma